3 Key Considerations When Choosing an Anticancer Wasting Treatment
Anticancer Wasting Treatment Development Trends
Research on treatments for muscle loss and weight reduction in cancer patients is actively progressing. Several new drug candidates, including Anamorelin, are entering clinical trials, with expectations that they will improve quality of life and survival rates for cancer patients.
Main Research Findings on Anticancer Wasting Treatments
A research team from Yonsei University and Seoul Women's University discovered a natural substance that prevents muscle loss in cancer patients. This substance has shown effectiveness in inhibiting muscle reduction, drawing attention for its potential clinical application. Additionally, MetaPharm's 'ASCA101CC,' an anticancer wasting treatment under development, has received approval for Phase 2 clinical trials in South Korea.
Prestige Biopharma IDC and Tortera Therapeutics are currently conducting joint research on antibody-based new drugs for anticancer wasting. Active development is also underway for new drug candidates that simultaneously address sarcopenia and cancer cachexia.
GC Green Cross Wellness has completed European clinical trials, while a research team from Kyungbuk National University and KAIST has developed a new drug candidate targeting both sarcopenia and anticancer wasting. This is expected to significantly aid in the overall health management of cancer patients.
Recent Advances in Anticancer Wasting Treatment Research
KAIST and Tortera Therapeutics are focusing on developing new drugs for cachexia, with recent reports as of August 2, 2026 indicating ongoing development of treatments to prevent cancer patients from wasting away. The Daegu University of Oriental Medicine research team has identified the earliest diagnostic genes for canine cancer cachexia worldwide, which may contribute to human disease research.
GIST researchers have identified the cause of muscle and weight loss in cancer patients for the first time globally. Based on this finding, RNA gene therapy technology is being developed with a goal of clinical application by 2030. This is expected to open a new era in anticancer wasting treatment.
Anticancer wasting is known as a serious complication that threatens patients' lives, and research is also underway on microbiome-based treatments. These are anticipated to play an important role in the overall health management of cancer patients.

Clinical Progress of Anticancer Wasting Treatments
MetaPharm's 'ASCA101CC' has received Phase 2 clinical trial approval in South Korea and has signed a joint development agreement with Emterra Pharma. This treatment focuses on preventing muscle loss in cancer patients.
The joint research between Prestige Biopharma IDC and Tortera Therapeutics began with an agreement signed on May 19, 2026, focusing on developing antibody-based new drugs for anticancer wasting. The study explores a novel approach to simultaneously treat sarcopenia and cancer cachexia.
GC Green Cross Wellness's completion of European clinical trials has been noted as an international achievement in anticancer wasting treatment development. The new drug candidate developed by Kyungbuk National University and KAIST is expected to be effective in improving both sarcopenia and anticancer wasting.
Causes and Early Diagnosis of Anticancer Wasting
GIST researchers identified the cause of muscle and weight loss in cancer patients for the first time globally, as reported on January 29, 2026. This finding serves as a crucial foundation for developing cachexia treatments.
The Daegu University of Oriental Medicine research team identified the earliest diagnostic genes for canine cancer cachexia worldwide on July 27, 2026. This discovery may also be applicable to human disease research.
Microbiome-based treatment methods have been mentioned in multiple reports since mid-August 2026, suggesting new possibilities for anticancer wasting treatment. These findings indicate that changes in gut microbiota composition are related to cachexia development.
Future Outlook and Research Directions
RNA gene therapy technology aims for clinical application by 2030, which is expected to increase cancer patients' survival rates from complications to as high as 90%. Significant progress has been made in the current research phase, with plans to verify effectiveness through future clinical trials.
The development of cachexia treatments by KAIST and Tortera Therapeutics was highlighted in reports dated August 2, 2026, focusing on simultaneously improving muscle loss and weight reduction. This research is expected to contribute to improved survival rates for cancer patients.
Cachexia guidelines were published on May 29, 2020, recommending enteral nutrition and pharmacological interventions. These serve as important standards for patient management.
Important Information to Verify
While numerous reports have covered anticancer wasting treatment development, some details remain in the research phase without confirmation. In particular, the 2030 clinical application plan for RNA gene therapy technology is tentative.
MetaPharm's 'ASCA101CC' has received Phase 2 clinical trial approval in South Korea but requires additional research and verification to obtain full approval. This is a standard step in the drug development process.
The joint research between Prestige Biopharma IDC and Tortera Therapeutics began with an agreement signed on May 19, 2026, and clinical trial results have not yet been publicly released. This provides clarity on the precise progress of development.
Frequently Asked Questions
What is the most important research area in anticancer wasting treatment development?
The most important research areas in anticancer wasting treatment development are preventing muscle loss and avoiding weight reduction. These directly improve patients' survival rates and quality of life.
Which companies have received Phase 2 clinical trial approval for anticancer wasting treatments?
MetaPharm's 'ASCA101CC' has received Phase 2 clinical trial approval in South Korea. This is considered an important advancement in the development of anticancer wasting treatments.
How can microbiome-based treatment methods help with anticancer wasting treatment?
Research findings indicate that changes in gut microbiota composition are related to cachexia development, leading to ongoing development of new treatments based on this. This suggests maintaining a balanced gut microbiome is important for cancer patients' health management.
Frequently Asked Questions
Anticancer wasting treatment development has been progressing actively in recent times. Key achievements include the discovery of natural substances by Yonsei University and Seoul Women's University research teams, Phase 2 clinical trial approval for MetaPharm's 'ASCA101CC,' completion of European clinical trials by GC Green Cross Wellness, and joint research between KAIST and Tortera Therapeutics. The identification of early diagnostic genes by Daegu University of Oriental Medicine has also provided new directions.
As anticancer wasting is known to be a life-threatening complication, the development of effective treatments is urgent. The 2030 target for clinical application of RNA gene therapy technology reflects these research achievements.
Future anticancer wasting treatment development will progress through multiple approaches including preventing muscle loss, avoiding weight reduction, and studying gut microbiota composition changes. This is expected to improve patients' quality of life and increase survival rates.
You can view similar articles on this topic all at once.
View Related ArticlesFAQ
What is the most important research area in anticancer wasting treatment development?
The most important research areas are preventing muscle loss and avoiding weight reduction, which directly improve patients' survival rates and quality of life.
Which companies have received Phase 2 clinical trial approval for anticancer wasting treatments?
MetaPharm's 'ASCA101CC' has received Phase 2 clinical trial approval in South Korea, marking a significant advancement in the field.
How can microbiome-based treatment methods help with anticancer wasting treatment?
Research shows that changes in gut microbiota composition are related to cachexia development, leading to new treatments focused on maintaining microbial balance for better cancer patient health management.
Korean Source
This article is an English localization of a Korean-language report from BlogScore. Original: 악액질 치료제 선택 시 주의해야 할 3가지